Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K announcing its chief commercial officer’s intent to resign.
Brian B. Hansen, EVP and CCO, notified the company of his decision to resign on Aug. 17. His resignation goes into effect on Dec. 31, 2023.
In connection with Hansen’s resignation, he and the automated insulin delivery technology maker entered into a separation agreement. Under this agreement, dated Aug. 18, Hansen remains employed until June 28, 2024. However, he will be on administrative leave after the Dec. 31, 2023, effective date.
Get the full story at our sister site, Drug Delivery Business News.